Table 1.
Characteristics of patients
| Characteristic | Drug-therapy group (n = 18) | Concurrent chemo-radiotherapy group (n = 23) | P | |
|---|---|---|---|---|
| Age, median (years) | 68.0 (46–84) | 62.0 (40–73) | 0.045 | |
| Sex | Female | 5 (27.8%) | 5 (21.7%) | 0.724 |
| Male | 13 (72.2%) | 18 (78.3%) | ||
| Smoking status | Never | 5 (27.8%) | 4 (17.4%) | 0.471 |
| Former or current | 13 (72.2%) | 19 (82.6%) | ||
| Brinkman index, median (pack-year) | 47 (0–90) | 40 (0–88) | 0.895 | |
| Histology | Adenocarcinoma | 10 (55.6%) | 14 (60.9%) | 0.760 |
| Squamous cell carcinoma | 7 (38.9%) | 7 (30.4%) | ||
| Others | 1 (5.6%) | 2 (8.7%) | ||
| Driver mutation | Present | 7 (46.7%) | 5 (29.4%) | 0.467 |
| (EGFR/ALK) | (5/2) | (4/1) | ||
| Clinical stage | II | 2 (11.1%) | 5 (21.7%) | 0.438 |
| (IIA/IIB) | (1/1) | (0/5) | ||
| III | 16 (88.9%) | 18 (78.3%) | ||
| (IIIA/IIIB/IIIC) | (9/3/4) | (11/6/1) | ||
| Radiotherapy dose (Gray) | – | 60 (30–70) | ||
| Drug therapy | Platinum doublet | 7 (38.9%) | 23 (100.0%) | <0.001 |
| Other cytotoxic regimen | 1 (5.6%) | 0 | ||
| Cisplatin (BAI) | 4 (22.2%) | 0 | ||
| TKI | 6 (33.3%) | 0 | ||
| (Gef/Erlo/Alec) | (4/1/1) | |||
| Pathologic response | Therapeutic effect 1 | 13 (72.2%) | 6 (26.1%) | 0.005 |
| Therapeutic effect 2 | 5 (27.8%) | 17 (73.9%) | ||
Data represented as absolute counts (%) or median (range)
EGFR epidermal growth factor receptor gene, ALK anaplastic large-cell lymphoma kinase gene, BAI bronchial arterial infusion, TKI tyrosine kinase inhibitor, Gef gefitinib, Erlo erlotinib, Alec alectinib
Therapeutic effect 1, residual viable cancer cells detected in ‘≥1/3’ of resected tumour
Therapeutic effect 2, residual viable cancer cells detected in ‘<1/3’ of resected tumour